Lefevre-Borg F, Lorrain J, Lechaire J, Thiry C, Lhoste F, Hicks P E, Cavero I
Laboratoires d'Etudes et de Recherches Synthélabo, Paris, France.
Fundam Clin Pharmacol. 1987;1(3):179-200. doi: 10.1111/j.1472-8206.1987.tb00557.x.
In normotensive anesthetized rats, 15-min IV infusions of quinpirole (2.5-40.0 micrograms/kg/min) produced dose-related, rapidly appearing, and long-lasting decreases in mean carotid artery BP and HR. Hemodynamically, the hypotensive effects of quinpirole (10.0 micrograms/kg/min) were due to a fall in total peripheral vascular resistance inasmuch as CO did not undergo significant changes. Mesenteric, hindquarter, and renal blood flows were, respectively, reduced, unchanged, and increased by quinpirole; thus, the renal vascular resistance fell more than either the total peripheral or hindquarter vascular resistance. Biochemically, the hypotensive effects of quinpirole were accompanied by a decrease in the plasma level of norepinephrine and plasma renin activity. The peak fall in blood pressure produced by quinpirole was not significantly modified by atenolol, idazoxan, ranitidine, SCH 23390 (DA1 dopamine receptor antagonist), enalapril, or SK&F 100273 (V1 vasopressin receptor antagonist), but was entirely blocked by S-sulpiride or removal of autonomic nerve drive to the cardiovascular system with chlorisondamine. The effect of quinpirole on systemic and regional vascular resistances was antagonized by S-sulpiride. Furthermore, SK&F 100273 prevented the fall in mesenteric flow produced by quinpirole. Intracerebroventricular injection of quinpirole (10.0 micrograms/kg over 2 min) in saline- or SK&F 100273-pretreated rats produced the same hypotensive effects as an identical IV dose of the compound. In pithed rats, quinpirole (10 micrograms/kg/min IV over 15 min) decreased pressor responses to electrical stimulation of spinal cord outflow without affecting those to exogenously injected angiotensin II, B-HT 920, cirazoline, norepinephrine, or 5-hydroxytryptamine. This inhibitory effect was antagonized by S-sulpiride. The bradycardia produced by quinpirole in intact rats was mediated by the autonomic nervous system inasmuch as it was slightly modified by bilateral vagotomy, partly reduced by atenolol, and entirely prevented by pithing even when the low HR of the last preparation had been raised by IV infusion of isoprenaline. Furthermore, S-sulpiride, but not SCH 23390 or idazoxan, antagonized this effect. In pithed rats, quinpirole similarly inhibited the tachycardic responses elicited by electrical stimulation of either the spinal cord outflow (preganglionic) or postganglionic cardioaccelerator nerve fibers. This effect of quinpirole was susceptible to S-sulpiride but not idazoxan blockade. Finally, in conscious spontaneously hypertensive rats (SHR) but not in normotensive rats, quinpirole (10 micrograms/kg/min IA over 15 min) lowered blood pressure.(ABSTRACT TRUNCATED AT 400 WORDS)
在血压正常的麻醉大鼠中,静脉输注喹吡罗15分钟(2.5 - 40.0微克/千克/分钟)可导致平均颈动脉血压和心率呈剂量相关、迅速出现且持久的下降。从血流动力学角度来看,喹吡罗(10.0微克/千克/分钟)的降压作用是由于总外周血管阻力下降,因为心输出量未发生显著变化。喹吡罗使肠系膜、后肢和肾血流量分别减少、不变和增加;因此,肾血管阻力的下降幅度大于总外周或后肢血管阻力。从生化角度来看,喹吡罗的降压作用伴随着去甲肾上腺素血浆水平和血浆肾素活性的降低。喹吡罗引起的血压峰值下降未被阿替洛尔、咪唑克生、雷尼替丁、SCH 23390(DA1多巴胺受体拮抗剂)、依那普利或SK&F 100273(V1血管加压素受体拮抗剂)显著改变,但被S-舒必利完全阻断,或通过用氯异吲哚铵消除对心血管系统的自主神经驱动而阻断。喹吡罗对全身和局部血管阻力的作用被S-舒必利拮抗。此外,SK&F 100273可防止喹吡罗引起的肠系膜血流量下降。在盐水或SK&F 100273预处理的大鼠中,脑室内注射喹吡罗(2分钟内10.0微克/千克)产生的降压作用与相同静脉剂量的该化合物相同。在脊髓毁损大鼠中,喹吡罗(10微克/千克/分钟静脉输注15分钟)降低了对脊髓传出神经电刺激的升压反应,而不影响对外源性注射的血管紧张素II、B-HT 920、可乐定、去甲肾上腺素或5-羟色胺的反应。这种抑制作用被S-舒必利拮抗。喹吡罗在完整大鼠中引起的心动过缓是由自主神经系统介导的,因为双侧迷走神经切断术对其有轻微改变,阿替洛尔可部分降低其作用,甚至在最后一组制备中通过静脉输注异丙肾上腺素提高低心率后,脊髓毁损仍可完全防止其发生。此外,S-舒必利而非SCH 23390或咪唑克生可拮抗这种作用。在脊髓毁损大鼠中,喹吡罗同样抑制了由脊髓传出神经(节前)或节后心脏加速神经纤维电刺激引起的心动过速反应。喹吡罗的这种作用对S-舒必利敏感,但不受咪唑克生阻断。最后,在清醒的自发性高血压大鼠(SHR)中而非血压正常的大鼠中,喹吡罗(10微克/千克/分钟腹腔注射15分钟)可降低血压。(摘要截取自400字)